Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies.

    Research output: Contribution to journalArticleAcademicpeer-review


    The poor translational validity of autoimmune-mediated inflammatory disease (AIMID) models in inbred and specific pathogen-free (SPF) rodents underlies the high attrition of new treatments for the corresponding human disease. Experimental autoimmune encephalomyelitis (EAE) is a frequently used preclinical AIMID model. We discuss here how crucial information needed for the innovation of current preclinical models can be obtained from postclinical analysis of the nonhuman primate EAE model, highlighting the mechanistic reasons why some therapies fail and others succeed. These new insights can also help identify new targets for treatment.
    Original languageUndefined/Unknown
    JournalDrug Discovery Today
    Publication statusPublished - 2 Apr 2014

    Cite this